When asked which area of innovation within Biopharma do you expect will have the biggest impact in 2024 the increase in respondents answering AI stands out, up to 20% from 12% last year. Within this, the number of institutional investors identifying AI has markedly increased, from 1% to 14%

Elsewhere, Targeted Therapies remains the number one area selected, but by an even greater number, 35% versus 23% this time last year. Vaccines and TCRs, both selected by 3%, have lost prominence.